Edition:
United States

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

0.86USD
8 Dec 2016
Change (% chg)

-- (--)
Prev Close
$0.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
29,274
52-wk High
$5.64
52-wk Low
$0.74

BIOC.OQ

Chart for BIOC.OQ

About

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally... (more)

Overall

Beta: --
Market Cap(Mil.): $14.97
Shares Outstanding(Mil.): 17.50
Dividend: --
Yield (%): --

Financials

  BIOC.OQ Industry Sector
P/E (TTM): -- 30.43 30.35
EPS (TTM): -2.64 -- --
ROI: -416.47 13.26 15.27
ROE: -1,587.60 17.03 16.60

BRIEF-Biocept reports Q3 loss per share $0.57

* Q3 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S

Nov 09 2016

BRIEF-Biocept voluntarily ended common stock purchase agreement that co entered into on Dec 21, 2015, with Aspire Capital Fund, LLC

* Biocept Inc - On Nov 4, 2016, co voluntarily ended common stock purchase agreement that co entered into on Dec 21, 2015, with Aspire Capital Fund, LLC Source text: [http://bit.ly/2f9IZ3a] Further company coverage:

Nov 04 2016

BRIEF-Milestone Investments reports 6.3 pct passive stake in Biocept

* Milestone Investments, LP reports 6.3 percent passive stake in Biocept Inc as of Oct 14 - SEC filing Source text: [http://bit.ly/2dDGE3A] Further company coverage:

Oct 24 2016

BRIEF-Ally Bridge LB Healthcare Master Fund Ltd reports 17.6 pct stake in Biocept

* Ally Bridge LB Healthcare Master Fund Limited reports a 17.6 percent stake in Biocept Inc as of Oct 14 - SEC Filing

Oct 20 2016

BRIEF-Sabby Management reports 6.51 pct passive stake in Biocept

* Sabby management llc reports 6.51 percent passive stake in biocept inc as of october 14 - sec filing Source text : http://bit.ly/2dZN2kB Further company coverage:

Oct 17 2016

BRIEF-Biocept says board approved reverse stock split at ratio of 1:3

* Proposal to amend co's certificate of amendment of certificate of incorporation approved by stockholders at special meeting - SEC filing

Sep 29 2016

BRIEF-Biocept expands Chinese patent protection covering key technologies

* Biocept expands Chinese patent protection covering key technologies for circulating tumor cell capture and analysis used in liquid biopsy tests

Sep 01 2016

BRIEF-Biocept reports agreement with Teneovita Medical

* Biocept announces agreement with Teneovita Medical to market and distribute its Liquid Biopsy testing platform in Canada

Aug 30 2016

BRIEF-Biocept files for common stock offering of up to $10 mln

* Files for common stock offering of up to $10 million - SEC Filing Source text: [http://bit.ly/2aSxvzR] Further company coverage:

Aug 12 2016

BRIEF-Biocept expands distribution of liquid biopsy tests to Philippines

* Biocept expands distribution of liquid biopsy tests to the Philippines

Aug 11 2016

Earnings vs. Estimates